{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:30:02Z","timestamp":1762324202537,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study was funded by the Rhode Island Science and Technology Advisory Council"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40262-017-0626-1","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T16:28:42Z","timestamp":1515774522000},"page":"1199-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations"],"prefix":"10.1007","volume":"57","author":[{"given":"Mwlod","family":"Ghareeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald Y.","family":"Gohh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-7615","authenticated-orcid":false,"given":"Fatemeh","family":"Akhlaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"issue":"Suppl. 3","key":"626_CR1","first-page":"S1","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work G","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl. 3):S1\u2013155.","journal-title":"Am J Transplant"},{"issue":"6","key":"626_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584\u201391.","journal-title":"Ther Drug Monit."},{"issue":"26","key":"626_CR3","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1056\/NEJMra033540","volume":"351","author":"PF Halloran","year":"2004","unstructured":"Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715\u201329.","journal-title":"N Engl J Med."},{"issue":"5","key":"626_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328\u201335.","journal-title":"Drug Metab Pharmacokinet."},{"issue":"9","key":"626_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","volume":"29","author":"H Blume","year":"2006","unstructured":"Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769\u201384.","journal-title":"Drug Saf."},{"issue":"8","key":"626_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/TP.0b013e318247a6c7","volume":"93","author":"DK Hooper","year":"2012","unstructured":"Hooper DK, Fukuda T, Gardiner R, Logan B, Roy-Chaudhury A, Kirby CL, et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. Transplantation. 2012;93(8):806\u201312.","journal-title":"Transplantation."},{"issue":"6","key":"626_CR7","doi-asserted-by":"publisher","first-page":"E217","DOI":"10.1111\/j.1399-3046.2011.01559.x","volume":"16","author":"M Maguire","year":"2012","unstructured":"Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant. 2012;16(6):E217\u201320.","journal-title":"Pediatr Transplant."},{"issue":"5","key":"626_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1345\/aph.1D366","volume":"38","author":"K Takahashi","year":"2004","unstructured":"Takahashi K, Motohashi H, Yonezawa A, Okuda M, Ito N, Yamamoto S, et al. Lansoprazole\u2014tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38(5):791\u20134.","journal-title":"Ann Pharmacother."},{"issue":"4","key":"626_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2165\/11317550-000000000-00000","volume":"49","author":"CE Staatz","year":"2010","unstructured":"Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet. 2010;49(4):207\u201321.","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"626_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/FTD.0b013e3182731809","volume":"34","author":"H Ro","year":"2012","unstructured":"Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim SJ, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34(6):680\u20135.","journal-title":"Ther Drug Monit."},{"issue":"2","key":"626_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.gene.2012.10.048","volume":"512","author":"Y Shi","year":"2013","unstructured":"Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512(2):226\u201331.","journal-title":"Gene."},{"issue":"2","key":"626_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/01.fpc.0000184953.31324.e4","volume":"16","author":"M Uesugi","year":"2006","unstructured":"Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genom. 2006;16(2):119\u201327.","journal-title":"Pharmacogenet Genom."},{"issue":"2","key":"626_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","volume":"53","author":"DA Hesselink","year":"2014","unstructured":"Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53(2):123\u201339.","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"626_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","volume":"18","author":"M Fukudo","year":"2008","unstructured":"Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genom. 2008;18(5):413\u201323.","journal-title":"Pharmacogenet Genom."},{"issue":"5","key":"626_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/pgs.10.43","volume":"11","author":"A Capron","year":"2010","unstructured":"Capron A, Mourad M, De Meyer M, De Pauw L, Eddour DC, Latinne D, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11(5):703\u201314.","journal-title":"Pharmacogenomics."},{"issue":"3","key":"626_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0149-2918(02)85038-X","volume":"24","author":"BD Kahan","year":"2002","unstructured":"Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24(3):330\u201350 (discussion 29).","journal-title":"Clin Ther."},{"issue":"10","key":"626_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353.","journal-title":"Clin Pharmacokinet."},{"issue":"2","key":"626_CR18","first-page":"140","volume":"21","author":"CY Cheung","year":"2008","unstructured":"Cheung CY, van der Heijden J, Hoogtanders K, Christiaans M, Liu YL, Chan YH, et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int. 2008;21(2):140\u20135.","journal-title":"Transpl Int."},{"issue":"1","key":"626_CR19","first-page":"3","volume":"24","author":"CS Ho","year":"2003","unstructured":"Ho CS, Lam CW, Chan MH, Cheung RC, Law LK, Lit LC, et al. Electrospray ionisation mass spectrometry: principles and clinical applications. Clin Biochem Rev. 2003;24(1):3\u201312.","journal-title":"Clin Biochem Rev."},{"issue":"3","key":"626_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.ftd.0000211826.65607.05","volume":"28","author":"AE Mendonza","year":"2006","unstructured":"Mendonza AE, Gohh RY, Akhlaghi F. Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit. 2006;28(3):402\u20136.","journal-title":"Ther Drug Monit."},{"issue":"4","key":"626_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/FTD.0b013e3182899ea2","volume":"35","author":"N Teeninga","year":"2013","unstructured":"Teeninga N, Guan Z, Freijer J, Ruiter AF, Ackermans MT, Kist-van Holthe JE, et al. Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ther Drug Monit. 2013;35(4):485\u201392.","journal-title":"Ther Drug Monit."},{"issue":"5","key":"626_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/00007691-200410000-00016","volume":"26","author":"A Mendonza","year":"2004","unstructured":"Mendonza A, Gohh R, Akhlaghi F. Determination of cyclosporine in saliva using liquid chromatography\u2013tandem mass spectrometry. Ther Drug Monit. 2004;26(5):569\u201375.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"626_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00467-010-1670-3","volume":"26","author":"V Belostotsky","year":"2011","unstructured":"Belostotsky V, Adaway J, Keevil BG, Cohen DR, Webb NJ. Measurement of saliva tacrolimus levels in pediatric renal transplant recipients. Pediatr Nephrol. 2011;26(1):133\u20138.","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"626_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007691-200406000-00013","volume":"26","author":"M Tennison","year":"2004","unstructured":"Tennison M, Ali I, Miles MV, D\u2019Cruz O, Vaughn B, Greenwood R. Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the US postal service. Ther Drug Monit. 2004;26(3):295\u20139.","journal-title":"Ther Drug Monit."},{"issue":"5","key":"626_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00007691-199410000-00001","volume":"16","author":"R Gorodischer","year":"1994","unstructured":"Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;16(5):437\u201343.","journal-title":"Ther Drug Monit."},{"key":"626_CR26","unstructured":"DrugBank. Tacrolimus. http:\/\/www.drugbank.ca\/drugs\/DB00864 . Accessed 12 May 2015."},{"key":"626_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1749-6632.1993.tb18347.x","volume":"694","author":"R Haeckel","year":"1993","unstructured":"Haeckel R. Factors influencing the saliva\/plasma ratio of drugs. Ann N Y Acad Sci. 1993;694:128\u201342.","journal-title":"Ann N Y Acad Sci."},{"issue":"5","key":"626_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","volume":"26","author":"H Zahir","year":"2004","unstructured":"Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit. 2004;26(5):506\u201315.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"626_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1056-8719(02)00158-2","volume":"46","author":"H Zahir","year":"2001","unstructured":"Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46(1):27\u201335.","journal-title":"J Pharmacol Toxicol Methods."},{"issue":"6","key":"626_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/FTD.0000000000000351","volume":"38","author":"NA Stienstra","year":"2016","unstructured":"Stienstra NA, Sikma MA, van Dapperen AL, de Lange DW, van Maarseveen EM. Development of a simple and rapid method to measure the free fraction of tacrolimus in plasma using ultrafiltration and LC\u2013MS\/MS. Ther Drug Monit. 2016;38(6):722\u20137.","journal-title":"Ther Drug Monit."},{"issue":"2","key":"626_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2125.1985.tb05050.x","volume":"20","author":"PA Reece","year":"1985","unstructured":"Reece PA, Disney AP, Stafford I, Shastry JC. Prednisolone protein binding in renal transplant patients. Br J Clin Pharmacol. 1985;20(2):159\u201362.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"626_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1373\/clinchem.2003.028266","volume":"50","author":"EB Schwartz","year":"2004","unstructured":"Schwartz EB, Granger DA. Transferrin enzyme immunoassay for quantitative monitoring of blood contamination in saliva. Clin Chem. 2004;50(3):654\u20136.","journal-title":"Clin Chem."},{"key":"626_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchromb.2016.10.008","volume":"1038","author":"M Ghareeb","year":"2016","unstructured":"Ghareeb M, Akhlaghi F. Development and validation of a sensitive and selective LC\u2013MS\/MS method for determination of tacrolimus in oral fluids. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1038:136\u201341.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"issue":"9","key":"626_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40262-013-0069-2","volume":"52","author":"K Ogasawara","year":"2013","unstructured":"Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2\/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52(9):751\u201362.","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"626_CR35","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.psyneuen.2007.05.003","volume":"32","author":"DA Granger","year":"2007","unstructured":"Granger DA, Cicchetti D, Rogosch FA, Hibel LC, Teisl M, Flores E. Blood contamination in children\u2019s saliva: prevalence, stability, and impact on the measurement of salivary cortisol, testosterone, and dehydroepiandrosterone. Psychoneuroendocrinology. 2007;32(6):724\u201333.","journal-title":"Psychoneuroendocrinology."},{"issue":"1","key":"626_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00007691-199902000-00003","volume":"21","author":"F Akhlaghi","year":"1999","unstructured":"Akhlaghi F, Ashley J, Keogh A, Brown K. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Ther Drug Monit. 1999;21(1):8\u201316.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"626_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00007890-199901150-00008","volume":"67","author":"F Akhlaghi","year":"1999","unstructured":"Akhlaghi F, Keogh AM, Brown KF. Unbound cyclosporine and allograft rejection after heart transplantation. Transplantation. 1999;67(1):54\u20139.","journal-title":"Transplantation."},{"issue":"8","key":"626_CR38","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/clinchem\/34.8.1545","volume":"34","author":"JE Coates","year":"1988","unstructured":"Coates JE, Lam SF, McGaw WT. Radioimmunoassay of salivary cyclosporine with use of 125I-labeled cyclosporine. Clin Chem. 1988;34(8):1545\u201351.","journal-title":"Clin Chem."},{"issue":"3","key":"626_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jpba.2009.05.030","volume":"50","author":"B Shen","year":"2009","unstructured":"Shen B, Li S, Zhang Y, Yuan X, Fan Y, Liu Z, et al. Determination of total, free and saliva mycophenolic acid with a LC\u2013MS\/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal. 2009;50(3):515\u201321.","journal-title":"J Pharm Biomed Anal."},{"key":"626_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","volume":"1241","author":"MH Wiesen","year":"2012","unstructured":"Wiesen MH, Farowski F, Feldkotter M, Hoppe B, Muller C. Liquid chromatography\u2013tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr A. 2012;1241:52\u20139.","journal-title":"J Chromatogr A."},{"issue":"3","key":"626_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpt1976203278","volume":"20","author":"RL Galeazzi","year":"1976","unstructured":"Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther. 1976;20(3):278\u201389.","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"626_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","volume":"36","author":"H Liu","year":"1999","unstructured":"Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999;36(6):453\u201370.","journal-title":"Clin Pharmacokinet."},{"issue":"10","key":"626_CR43","first-page":"468","volume":"15","author":"K Feller","year":"1977","unstructured":"Feller K, le Petit G. On the distribution of drugs in saliva and blood plasma. Int J Clin Pharmacol Biopharm. 1977;15(10):468\u20139.","journal-title":"Int J Clin Pharmacol Biopharm."},{"issue":"6","key":"626_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1601-0825.2007.01415.x","volume":"14","author":"C Kragelund","year":"2008","unstructured":"Kragelund C, Hansen C, Torpet LA, Nauntofte B, Brosen K, Pedersen AM, et al. Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. Oral Dis. 2008;14(6):533\u201340.","journal-title":"Oral Dis."},{"issue":"6","key":"626_CR45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0003-9969(01)00012-7","volume":"46","author":"T Uematsu","year":"2001","unstructured":"Uematsu T, Yamaoka M, Matsuura T, Doto R, Hotomi H, Yamada A, et al. P-glycoprotein expression in human major and minor salivary glands. Arch Oral Biol. 2001;46(6):521\u20137.","journal-title":"Arch Oral Biol."},{"issue":"1","key":"626_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0003-9969(02)00159-0","volume":"48","author":"T Uematsu","year":"2003","unstructured":"Uematsu T, Yamaoka M, Doto R, Tanaka H, Matsuura T, Furusawa K. Expression of ATP-binding cassette transporter in human salivary ducts. Arch Oral Biol. 2003;48(1):87\u201390.","journal-title":"Arch Oral Biol."},{"issue":"1","key":"626_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/FPC.0b013e3283349eb0","volume":"20","author":"RH Ho","year":"2010","unstructured":"Ho RH, Leake BF, Kilkenny DM, Zu Schwabedissen HEM, Glaeser H, Kroetz DL, et al. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genom. 2010;20(1):45\u201357.","journal-title":"Pharmacogenet Genom."},{"issue":"5","key":"626_CR48","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3109\/0886022X.2013.780621","volume":"35","author":"DK Yadav","year":"2013","unstructured":"Yadav DK, Gera DN, Gumber MR, Kute VB, Patel MP, Vanikar AV, et al. Tacrolimus-induced severe cholestasis complicating renal transplantation. Ren Fail. 2013;35(5):735\u20137.","journal-title":"Ren Fail."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0626-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0626-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0626-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T15:23:19Z","timestamp":1603639399000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0626-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0626-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"12 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by the Rhode Island Science and Technology Advisory Council and the University of Rhode Island, College of Pharmacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mwlod Ghareeb, Reginald Y. Gohh, and Fatemeh Akhlaghi have no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}